T1	p 92 114	stable COPD patients .
T2	p 129 158	COPD patients , reversibility
T3	p 220 226	volume
T4	p 596 630	60 COPD patients underwent dyspnea
T5	p 789 800	?sRAW-based
T6	p 842 853	45 patients
T7	p 1250 1287	patients were stratified according to
T8	p 1424 1432	criteria
T9	i 241 246	) and
T10	i 276 277	)
T11	i 331 346	bronchodilators
T12	i 392 400	trapping
T13	i 462 470	specific
T14	i 505 506	)
T15	i 556 573	bronchodilators .
T16	i 718 725	placebo
T17	i 729 746	300?g indacaterol
T18	i 931 938	?ITGV )
T19	i 982 987	?RV )
T20	i 1013 1017	?FVC
T21	i 1045 1049	?VAS
T22	i 1108 1112	?FVC
T23	i 1192 1195	?RV
T24	i 1352 1367	bronchodilators
T25	i 1509 1518	mechanics
T26	o 20 40	acute bronchodilator
T27	o 63 88	airway resistance changes
T28	o 202 229	forced expiratory volume at
T29	o 247 270	forced vital capacity (
T30	o 310 323	smooth muscle
T31	o 371 423	hyperinflation , gas trapping , and possibly dyspnea
T32	o 471 498	airway resistance changes (
T33	o 631 686	evaluation ( VAS score ) and pulmonary function testing
T34	o 772 784	Spirographic
T35	o 871 876	?sRAW
T36	o 904 936	intrathoracic gas volume ( ?ITGV
T37	o 964 985	residual volume ( ?RV
T38	o 1013 1017	?FVC
T39	o 1045 1049	?VAS
T40	o 1172 1177	?ITGV
T41	o 1192 1195	?RV
T42	o 1214 1218	?VAS
T43	o 1231 1232	)
T44	o 1331 1341	functional
T45	o 1465 1530	bronchodilator-induced improvements of lung mechanics and dyspnea